Tengion, Inc.

Equities

TNGNQ

US88034G2084

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:10:10 2024-02-02 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2023	Tengion, Inc. Went Out of Business	CI
2022	Bankruptcy Judge Changed for Tengion, Inc.	CI

Bankruptcy Judge Changed for Tengion, Inc.

February 24, 2022 at 11:00 pm EST

The US Bankruptcy Court granted an order for the change of Judge for the bankruptcy case of Tengion, Inc. on February 25, 2022. J Kate Stickles has been appointed as the Judge replacing Christopher S. Sontchi.

Latest news about Tengion, Inc.

Tengion, Inc. Went Out of Business	Nov. 19	CI
Bankruptcy Judge Changed for Tengion, Inc.	22-02-24	CI
RegenMedTX, LLC completed the acquisition of substantially all assets from Tengion, Inc. (OTCPK:TNGN.Q).	15-03-31	CI
Motion for Private Asset Sale Approved for Tengion, Inc.	15-03-05	CI
Order Approving Private Sale Agreement for Tengion, Inc.	15-02-19	CI
Motion for Asset Sale Filed by Chapter 7 Trustee for Tengion, Inc.	15-02-11	CI
RegenMedTX, LLC signed an agreement to acquire substantially all assets from Tengion, Inc. (OTCPK:TNGN.Q) for $22.1 million.	15-02-11	CI
Tengion, Inc. will Change its Ticker to TNGNQ from TNGN	14-12-31	CI
Tengion, Inc. Filed for Bankruptcy	14-12-28	CI
Tengion, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	14-11-14	CI
Tengion Considers A Strategic Review	14-09-22	CI
Tengion, Inc. Announces Unaudited Earnings Results for Second Quarter and Six Months Ended June 30, 2014; Provides Clinical Update	14-08-13	CI
Tengion, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014	14-05-15	CI
Tengion, Inc. Auditor Raises 'Going Concern' Doubt	14-03-26	CI
Tengion, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013	14-03-26	CI
Tengion, Inc. Announces Continued Clinical Progress in its Two Lead Programs	14-01-13	CI
Tengion, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2013	13-08-14	CI
Tengion, Inc. Promotes A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance	13-08-07	CI
Tengion, Inc. announced that it has received $18.60 million in funding from a group of investors.	13-06-28	CI
Tengion, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013	13-05-15	CI
Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden	13-04-01	CI
Tengion, Inc. Auditor Raises 'Going Concern' Doubt	13-03-26	CI
Transcript : Tengion, Inc., Q4 2012 Earnings Call, Mar 18, 2013	13-03-18
Tengion, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2012	13-03-18	CI
Tengion, Inc. Announces Clinical Progress for Neo-Urinary Conduit Phase 1 Trial and Regulatory Advance for Neo-Kidney Augment	13-01-30	CI

Chart Tengion, Inc.

Duration

Period

More charts

Company Profile

Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Â The Company, by using its Organ Regeneration Platform, it creates neo-organs using patientâs own cells. Â The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Companyâs product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Medical Devices

	1st Jan change	Capi.
TENGION, INC.	-.--%	40
NIBEC CO., LTD.	-20.60%	128M
COLLPLANT BIOTECHNOLOGIES LTD.	-7.82%	67.46M
NOVACYT	+14.87%	61.68M
KIM FOREST ENTERPRISE CO., LTD.	+6.64%	60.58M
BONUS BIOGROUP LTD.	+0.60%	51.45M

Bio Medical Devices